One key to understanding this new economy: synthetic cannabinoids are simply misplaced pharmaceutical cannabinoids and they work great in one place: research laboratories.
Cannabinoids are in our research labs, sold in white powders by pharmaceutical companies, and now there are pharmaceutical companies placing “green” cannabinoids in pills and sprays and ointments. Suddenly, even for those of us somewhat familiar with the terrain, all the words started blending together like a smoothie.
Publius of The Cannabis Papers found these distinctions useful:
Three Types of Cannabinoid Businesses
These businesses use synthetic cannabinoid in research and in products like Marinol, a synthetic-THC available as a prescription pharmaceutical.
These are new businesses like GW Pharmaceutical; their product Nabiximols (Sativex) is made from plant cannabinoids-yet-pharmaceutical-grade.
This would be perhaps the most varied business group; it would include hemp foods, such businesses as Dr. Bronner's hemp oil soaps, herbal (raw, phyto-) cannabinoid medical dispensaries, as well as all collective and individual home-grow businesses.
Standardization is the next issue for green cannabinoids, and it’s trifold: the plant varies as well as one’s CS (biology) and the human condition (physiology and psychology). As herbaceutical companies grow and prosper, the listing of the cannabinoids in the product implies (and requires) a basic knowledge of one’s CS; that’s when cannabinoids will not only be a source of bodily health – they’ll also become a source of economic health.
Tomorrow: An update on Cannabinoids and Passing the Alzheimer’s Test.
Posted by Bryan W. Brickner